Provided by Tiger Trade Technology Pte. Ltd.

Veracyte

41.47
-0.8400-1.99%
Post-market: 41.850.3808+0.92%18:45 EDT
Volume:1.17M
Turnover:48.28M
Market Cap:3.33B
PE:29.74
High:42.07
Open:42.00
Low:41.02
Close:42.31
52wk High:60.91
52wk Low:28.25
Shares:80.39M
Float Shares:78.97M
Volume Ratio:0.90
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.39
EPS(LYR):0.8200
ROE:8.77%
ROA:4.09%
PB:2.40
PE(LYR):50.57

Loading ...

Veracyte VP, Chief Accounting Officer Jonathan Wygant sells 24,000 shares for $1.09 million

Reuters
·
May 28

Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo

Reuters
·
May 27

Analysts Are Bullish on These Healthcare Stocks: Veracyte (VCYT), Decibel Cannabis Company (DBCCF)

TIPRANKS
·
May 24

Veracyte director Robert S. Epstein sells 10,000 shares for $440,129

Reuters
·
May 23

Veracyte says OPTIMA trial backs Prosigna-guided chemotherapy decisions in breast cancer

Reuters
·
May 22

Optima Trial Results to Be Presented at Asco Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer

THOMSON REUTERS
·
May 22

Why Veracyte (VCYT) Is Up 5.4% After Medicare Backs Its TrueMRD Bladder Cancer Test

Simply Wall St.
·
May 21

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Tonix Pharma (TNXP) and Regeneron (REGN)

TIPRANKS
·
May 18

Veracyte TrueMRD test wins Medicare coverage for muscle-invasive bladder cancer monitoring

Reuters
·
May 15

Veracyte Secures Medicare Coverage for Truemrd Monitoring Test in Muscle-Invasive Bladder Cancer

THOMSON REUTERS
·
May 15

Veracyte Inc - Truemrd Monitoring Test Available for Order June 1, 2026

THOMSON REUTERS
·
May 15

Veracyte SVP, General Counsel Annie McGuire disposes 10,204 shares for $398,130.10

Reuters
·
May 09

Veracyte price target raised to $42 from $40 at Canaccord

TIPRANKS
·
May 07

Veracyte price target raised to $52 from $48 at UBS

TIPRANKS
·
May 07

Veracyte (VCYT) Margin Expansion And 166% Earnings Growth Test Premium Valuation Narratives

Simply Wall St.
·
May 07

Veracyte Is Maintained at Buy by UBS

Dow Jones
·
May 07

Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades

Stock Track
·
May 06

UBS Adjusts Price Target on Veracyte to $52 From $48, Maintains Buy Rating

MT Newswires Live
·
May 06

Stock Track | Veracyte Soars 13.77% in Pre-market on Strong Q1 Earnings Beat and Raised 2026 Guidance

Stock Track
·
May 06

Stock Track | Veracyte Soars 7.73% on Strong Q1 Earnings Beat and Raised 2026 Guidance

Stock Track
·
May 06